Actively Recruiting
SB17170 Phase 1 Clinical Trial in Solid Tumors
Led by SPARK Biopharma · Updated on 2025-11-20
50
Participants Needed
3
Research Sites
271 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
CONDITIONS
Official Title
SB17170 Phase 1 Clinical Trial in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of locally advanced or metastatic solid tumors confirmed by biopsy
- Failure or resistance to known standard treatments with no remaining standard options
- At least one measurable tumor lesion based on RECIST v1.1 criteria
- ECOG Performance Status of 0 or 1
- Expected survival of at least 3 months as assessed by the investigator
You will not qualify if you...
- Previous treatment with drugs targeting High Mobility Group Box 1 (HMGB1)
- Chemotherapy, radiation, immunotherapy, hormone therapy, targeted therapy, biological products, or tumor embolization within 28 days before starting the study drug
- Need to take prohibited medications or expected to take them during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Asan Medical Center
Seoul, South Korea
Not Yet Recruiting
2
Seoul National University Hospital
Seoul, South Korea
Not Yet Recruiting
3
Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
S
Sun Bin Kang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here